6 курс / Медицинская реабилитация, ЛФК, Спортивная медицина / МЕХАНИЗМЫ_ВЛИЯНИЯ_ИНДУЦИРУЕМОЙ_АЦЕТИЛХОЛИНЭСТЕРАЗОЙ_ОЛИГОМЕРИЗАЦИИ

101

84.Ikonomovic M.D. Cortical alpha7 nicotinic acetylcholine receptor and beta–amyloid levels in early Alzheimer disease./ M.D. Ikonomovic, L. Wecker, E.E. Abrahamson, J. Wuu, S.E. Counts, S.D. Ginsberg, E.J. Mufson, S.T. Dekosky.// Arch Neurol, 2009. – Vol. 66. – P. 646–651.

85.Inestrosa N.C. Acetylcholinesterase accelerates assembly of amyloid–beta–peptides into Alzheimer's fibrils: possible role of the peripheral site of the enzyme./ N.C. Inestrosa, A. Alvarez, C.A. Perez, R.D. Moreno, M. Vicente, C. Linker, O.I. Casanueva, C. Soto, J. Garrido.// Neuron, 1996. – Vol. 16(4). – P. 881–891.

86.Inestrosa N.C. Amyloid–cholinesterase interactions. Implications for Alzheimer's disease./ N.C. Inestrosa, M.C. Dinamarca, A. Alvarez.// FEBS J., 2008. – Vol. 275(4). – P. 625–632.

87.Iqbal K. Tau pathology in Alzheimer disease and other tauopathies./ K. Iqbal, C. Alonso Adel, S. Chen, M.O. Chohan, E. El-Akkad, C.X. Gong, S. Khatoon, B. Li, F. Liu, A. Rahman, H. Tanimukai, I. Grundke-Iqbal.// Biochim Biophys Acta, 2005. – Vol. 1739. – P. 198–210.

88.Isaacs A.M. Acceleration of amyloid beta–peptide aggregation by physiological concentrations of calcium./ A.M. Isaacs, D.B. Senn, M. Yuan, J.P. Shine, B.A. Yankner.// J Biol Chem., 2006. – Vol. 281. – P. 27916–27923.

89.Ittner L.M. Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer’s disease mouse models./ L.M. Ittner, Y.D. Ke, F. Delerue, M. Bi, A. Gladbach, J. van

Eersel, H. Wölfing, B.C. Chieng, M.J. Christie, I.A. Napier, A. Eckert, M.

Staufenbiel, E. Hardeman, J. Götz.// Cell, 2010. – Vol. 142. – P. 387–397. 90.Iwatsubo T. Visualization of A beta 42(43) and A beta 40 in senile plaques with

end–specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43)./ T. Iwatsubo, A. Odaka, N. Suzuki, H. Mizusawa, N. Nukina, Y. Ihara.// Neuron, 1994. – Vol. 13. – P. 45–53.

91.Jackson J. Targeting the synapse in Alzheimer's disease./ J. Jackson, E. Jambrina, J. Li, H. Marston, F. Menzies, K. Phillips, G. Gilmour.// Front Neurosci., 2019. – Vol. 13:735.

t.me/medicina_free

102

92.Janssen J.C. Early onset familial Alzheimer’s disease: mutation frequency in 31 families./ J.C. Janssen, J.A. Beck, T.A. Campbell, A. Dickinson, N.C. Fox, R.J. Harvey, H. Houlden, M.N. Rossor, J. Collinge.// Neurology, 2003. – Vol. 60. – P. 235–239.

93.Jiang N. Novel chromanone-dithiocarbamate hybrids as multifunctional AChE inhibitors with β-amyloid anti-aggregation properties for the treatment of Alzheimer's disease./ N. Jiang, J. Ding, J. Liu, X. Sun, Z. Zhang, Z. Mo, X. Li, H. Yin, W. Tang, S.S. Xie.// J Biol Chem., 2019:103027.

94.Kamenetz F. APP processing and synaptic function./ F. Kamenetz, T. Tomita, H. Hsieh, G. Seabrook, D. Borchelt, T. Iwatsubo, S. Sisodia, R. Malinow.// Neuron., 2003. – Vol. 37. – P. 925–937.

95.Kanemitsu H. Human neprilysin is capable of degrading amyloid beta peptide not only in the monomeric form but also the pathological oligomeric form./ H. Kanemitsu, T. Tomiyama, H. Mori.// Neurosci Lett., 2003. – Vol. 350. – P. 113–116.

96.Kar S. Interactions between beta–amyloid and central cholinergic neurons: implications for Alzheimer's disease./ S. Kar, S.P. Slowikowski, D. Westaway, H.T. Mount.// J Psychiatry Neurosci., 2004. – Vol. 29(6). – P. 427–441.

97.Kayed R. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis./ R. Kayed, E. Head, J.L Thompson, T.M. McIntire, S.C. Milton, C.W. Cotman, C.G. Glabe.// Science, 2003. – Vol. 300. – P. 486–489.

98.Kharlamova A.D. Slow–binding inhibition of acetylcholinesterase by an alkylammonium derivative of 6–methyluracil: mechanism and possible advantages for myasthenia gravis treatment./ A.D. Kharlamova, S.V. Lushchekina, K.A. Petrov, E.D. Kots, F. Nachon, M. Villard–Wandhammer, I.V. Zueva, E. Krejci, V.S. Reznik, V.V. Zobov, E.E. Nikolsky, P. Masson Biochem J., 2016. – Vol. 473(9). – P. 1225– 1236.

99.Khlistunova I. Inducible expression of Tau repeat domain in cell models of tauopathy: aggregation is toxic to cells but can be reversed by inhibitor drugs./ I. Khlistunova, J. Biernat, Y. Wang, M. Pickhardt, M. von Bergen, Z. Gazova, E. Mandelkow, E.M. Mandelkow.// J Biol Chem., 2006. – Vol. 281. – P. 1205–1214.

t.me/medicina_free

103

100.Kim S.H. Enhanced release of secreted form of Alzheimer's amyloid precursor protein from PC12 cells by nicotine./ S.H. Kim, Y.K. Kim, S.J. Jeong, C. Haass, Y.H. Kim, Y.H. Suh.// Mol Pharmacol., 1997. – Vol. 52(3). – P. 430–436.

101.Klein W. Targeting small Aβ oligomers: the solution to an Alzheimer's disease

conundrum?/ W. Klein.// Trends in Neurosciences, 2001. – Vol. 24. – P. 219–224. 102. Klyubin I. Amyloid beta protein dimer–containing human CSF disrupts synaptic

plasticity: prevention by systemic passive immunization./ I. Klyubin, V. Betts, A.T. Welzel, K. Blennow, H. Zetterberg, A. Wallin, C.A. Lemere, W.K. Cullen, Y. Peng, T. Wisniewski, D.J. Selkoe, R. Anwyl, D.M. Walsh, M.J. Rowan. J Neurosci., 2008.

– Vol. 28. – P. 4231–4237.

103.Koffie R.M. Oligomeric amyloid beta associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques./ R.M. Koffie, M. Meyer–

Luehmann, T. Hashimoto, K.W. Adams, M.L. Mielke, M. Garcia–Alloza, K.D. Micheva, S.J. Smith, M.L. Kim, V.M. Lee, B.T. Hyman, T.L. Spires–Jones.// Proc Natl Acad Sci USA., 2009. – Vol. 106(10). – P. 4231–4237.

104.Kourie J.I. Mechanisms of amyloid beta protein–induced modification in ion transport systems: implications for neurodegenerative diseases./ J.I. Kourie.// Cell Mol Neurobiol., 2001. – Vol. 21(3). – P. 173–213.

105.LaFerla F.M. Calcium dyshomeostasis and intracellular signalling in Alzheimer's disease./ F.M. LaFerla.// Nat Rev Neurosci., 2002. – Vol. 3. – P. 862–872.

106.Lahiri D.K. Cholinesterase inhibitors, beta–amyloid precursor protein and amyloid beta–peptides in Alzheimer's disease./ D.K. Lahiri, M.R. Farlow, N. Hintz, T. Utsuki, N.H. Greig.// Acta Neurol Scand Suppl., 2000. – Vol. 176. – P. 60–67.

107.Leissring M.A. Enhanced proteolysis of beta–amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death./ M.A. Leissring, W. Farris, A.Y. Chang, D.M. Walsh, X. Wu, X. Sun, M.P. Frosch, D.J. Selkoe.// Neuron, 2003. – Vol. 40. – P. 1087–1093.

108.LeVine H. 3rd Thioflavine T interaction synthetic Alzheimer's disease beta–

amyloid peptides: detection of amyloid aggregation in solution./ Н. LeVine 3rd.//

Protein Sci., 1993. – Vol. 2(3). – P. 404 – 410.

t.me/medicina_free

104

109. Li Y. Interleukin–1 mediates pathological effects of microglia on tau phosphorylation and on synaptophysin synthesis in cortical neurons through a p38– MAPK pathway./ Y. Li, L. Liu, S.W. Barger, W.S. Griffin.// J Neurosci, 2003. – Vol. 23. – P. 1605–1611.

110.Long J.N. Alzheimer disease: an update on pathobiology and treatment strategies./ J.M. Long, D.M. Holtzman.// Neurobiology of Aging, 2019. – Vol. 179(2). – P. 312–339.

111.Lopez Salon M. Defective ubiquitination of cerebral proteins in Alzheimer's disease./ M. Lopez Salon, L. Morelli, E.M. Castano, E.F. Soto, J.M. Pasquini.// J Neurosci Res., 2000. – Vol. 62. – P. 302–310.

112.Lue L.F. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease./ L.F. Lue, Y.M. Kuo, A.E. Roher, L. Brachova, Y. Shen, L. Sue, T. Beach, J.H. Kurth, R.E. Rydel, J. Rogers.// Am J Pathol., 1999. –

Vol. 155. – P. 853–862.

113.Lustbader J.W. ABAD directly links Abeta to mitochondrial toxicity in Alzheimer's disease./ J.W. Lustbader, M. Cirilli, K. Takuma, N. Wang, C. Caspersen, X. Chen, S. Pollak, M. Chaney, F. Trinchese, S. Liu, F. Gunn–Moore, L.F. Lue, D.G. Walker, P. Kuppusamy, Z.L. Zewier, O. Arancio, D. Stern, S.S. Yan, H. Wu.// Science, 2004. – Vol. 304(5669). – P. 448–452.

114.Mann D.M. Amyloid (Abeta) deposition in chromosome 1–linked Alzheimer’s

disease: the Volga German families./ D.M. Mann, T. Iwatsubo, D. Nochlin, S.M. Sumi, E. Levy-Lahad, T.D. Bird.// Ann Neurol., 1997. – Vol. 41(1). – P. 52–57.

115. Mann D.M. Pyramidal nerve cell loss in Alzheimer’s disease. /D.M. Mann.//

Neurodegeneration, 1996. – Vol. 5. – P. 423–427.

116.Marsh J. Synaptic dysfunction in Alzheimer's disease: the effects of amyloid beta on synaptic vesicle dynamics as a novel target for therapeutic intervention./ J. Marsh, P. Alifragis.// Neural Regen Res, 2018. – Vol. 13(4). – P. 616–623.

117.Martins R.N. Increased cerebral glucose-6-phosphate dehydrogenase activity in Alzheimer's disease may reflect oxidative stress./ R.N. Martins, C.G. Harper, G.B. Stokes, C.L. Masters.// J. Neurochem., 1986. – Vol. 46. – P. 1042–1045.

t.me/medicina_free

105

118.Masliah E. Synaptic and neuritic alterations during the progression of Alzheimer's disease./ E. Masliah, M. Mallory, L. Hansen, R. DeTeresa, M. Alford, R. Terry.// Neurosci. Lett., 1994. – Vol. 174(1). – P. 67–72.

119.Maurer S.V. The Cholinergic system modulates memory and hippocampal plasticity via its interactions with non-neuronal cells./ S.V. Maurer, C.L. Williams.// Front Immunol., 2017. – Vol. 8:1489.

120.McKhann G.M. The diagnosis of dementia due to Alzheimer’s disease:

recommendations from the National Institute on Aging–Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease./ G.M. McKhann, D.S. Knopman, H. Chertkow, B.T. Hyman, C.R. Jack Jr, C.H. Kawas, W.E. Klunk, W.J. Koroshetz, J.J. Manly, R. Mayeux, R.C. Mohs, J.C. Morris, M.N. Rossor, P. Scheltens, M.C. Carrillo, B. Thies, S. Weintraub, C.H. Phelps.// Alzheimers Dement., 2011. – Vol. 7(3). – P. 2639.

121.Mecocci P. Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease./ P. Mecocci, U. MacGarvey, M.F. Beal.// Ann. Neurol., 1994. – Vol. 36. –

P.747–751.

122.Medeiros R. alpha7 Nicotinic receptor agonist enhances cognition in aged 3xTgAD mice with robust plaques and tangles./ R. Medeiros, N. A. Castello, D. Cheng,

M.Kitazawa, D. Baglietto-Vargas, K. N. Green, T. A. Esbenshade, R. S. Bitner, M.

W.Decker, F. M. LaFerla.// Am J Pathol, 2013. – Vol. 184. – P. 520–529.

123.Menting K.W. β–secretase inhibitor; a promising novel therapeutic drug in Alzheimer's disease./ K.W. Menting, J.A. Claassen.// Front Aging Neurosci., 2014. –

Vol. 6. – P. 165.

124. Meyer–Luehmann M. A reporter of local dendritic translocation shows plaque– related loss of neural system function in APP–transgenic mice./ M. Meyer– Luehmann, M. Mielke, T.L. Spires–Jones, W. Stoothoff, P. Jones, B.J. Bacskai, B.T. Hyman.// J Neurosci., 2009. – Vol. 29(40). – P. 12636–12640.

125.Mori F. Cholinesterase inhibitors increase secretion of APPs in rat brain cortex./ F. Mori, C.C. Lai, F. Fusi, E. Giacobini.// Neuroreport., 1995. – Vol. 6(4). – P. 633–

636.

t.me/medicina_free

106

126.Morley J.E. A physiological role for amyloid-beta protein:enhancement of learning and memory./ J.E. Morley, S.A. Farr, W.A. Banks, S.N. Johnson, K.A.Yamada, L. Xu. // J Alzheimers Dis., 2010. – Vol. 19(2). – P. 441-149.

127.Morris J.C. Pathologic correlates of nondemented aging, mild cognitive impairment, and early–stage Alzheimer’s disease./ J.C. Morris, J.L. Price.// J Molec

Neurosci., 2001. – Vol. 17. – P. 101–118.

128.Morris R.G.M. The role of NMDA receptors in learning and memory. In the NMDA receptors./ R.G.M. Morris, M. Davis – Oxford: Oxford University Press, 1994. – 340-75 p.

129.Mungarro–Menchaca X. beta–Amyloid peptide induces ultrastructural changes in synaptosomes and potentiates mitochondrial dysfunction in the presence of ryanodine./ X. Mungarro–Menchaca, P. Ferrera, J. Moran, C. Arias.// J Neurosci Res., 2002. – Vol. 68. – P. 89–96.

130.Munoz F.J. Neurotoxicity of acetylcholinesterase amyloid beta-peptide aggregates is dependent on the type of Abeta peptide and the AChE concentration present in the complexes./ F.J. Munoz, N.C. Inestrosa.// FEBS Lett., 1999. – Vol. 450(3). – P. 205–209.

131.Naslund J. Correlation between elevated levels of amyloid beta–peptide in the brain and cognitive decline./ J. Naslund, V. Haroutunian, R. Mohs, K.L. Davis, P. Davies, P. Greengard, J.D. Buxbaum.// JAMA, 2000. – Vol. 283. – P. 1571–1577.

132.Neary D. Alzheimer’s disease: a correlative study./ D. Neary, J.S. Snowden, D.M.

Mann, D.M. Bowen, N.R. Sims, B. Northen, P.O. Yates, A.N. Davison.// J Neurol

Neurosurg Psychiatry, 1986. – Vol. 49. – P. 229–237.

133.Nicolas M. Amyloid precursor protein and neural development./ M. Nicolas, B.A. Hassan.// Development, 2014. – Vol. 141(13). – P. 2549–2548.

134.Nilsson L. Physostigmine restores [3H]–acetylcholine eZux from Alzheimer brain slices to normal level./ L. Nilsson, A. Nordberg, J. Hardy, P. Wester, B. Winblad.// J Neural Transm., 1986. – Vol. 67. – P. 275–285.

t.me/medicina_free

107

135. Nitsch R.M. From acetylcholine to amyloid: neurotransmitters and the pathology of Alzheimer's disease./ R.M. Nitsch.// Neurodegeneration, 1996. – Vol. 5. – P. 477– 482.

136.Nitsch R.M. Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors./ R.M. Nitsch, B.E. Slack, R.J. Wurtman, J.H. Growdon.// Science., 1992. – Vol. 258(5080). – P. 304–307.

137.Nordberg A. Nicotinic and muscarinic subtypes in the human brain: changes with aging and dementia./ A. Nordberg, I. Alafuzoff, B. Winblad.// J Neurosci Res., 1992.

–Vol. 31(1). – P. 103–111.

138.Nunomura A. Oxidative damage is the earliest event in Alzheimer disease./ A. Nunomura, G. Perry, G. Aliev, K. Hirai, A. Takeda, E.K. Balraj, P.K. Jones, H. Ghanbari, T. Wataya, S. Shimohama, S. Chiba, C.S. Atwood, R.B. Petersen, M.A. Smith.// J Neuropathol Exp Neurol., 2001. – Vol. 60. – P. 759–767.

139.Nussbaum R.L. Alzheimer's disease and Parkinson's disease./ R.L. Nussbaum, C.E. Ellis. N. Engl.// J Med., 2003. – Vol. 348(14). – P. 1356–1364.

140.Ott A. Prevalence of Alzheimer’s disease and vascular dementia: association with

education. The Rotterdam study./ A. Ott, M.M. Breteler, F. van Harskamp, J.J. Claus, T.J. van der Cammen, D.E. Grobbee, A. Hofman.// BMJ, 1995. – Vol. 310. –

P.9703.

141.Oxford A.E. Clinical trials in Alzheimer's disease: a hurdle in the path of remedy./ A.E Oxford, E.S. Stewart, T.T. Rohn.// Int J Alzheimers Dis., 2020:5380346.

142.Palmer A.M. Possible neurotransmitter basis of behavioral changes in

Alzheimer’s disease./ A.M. Palmer, G.C. Stratmann, A.W. Procter, D.M. Bowen.//

Ann Neurol., 1988. – Vol. 23. – P. 616–620.

143.Palmer A.M. Selective increase in lipid peroxidation in the inferior temporal cortex in Alzheimer's disease./ A.M. Palmer, M.A. Burns.// Brain Res., 1994. – Vol. 645(1-2). – P. 338–342.

144.Panza F. Tau-Centric Targets and Drugs in Clinical Development for the Treatment of Alzheimer's Disease./ F. Panza, V. Solfrizzi, D. Seripa, B.P. Imbimbo,

t.me/medicina_free

108

M. Lozupone, A. Santamato, C. Zecca, M.R. Barulli, A. Bellomo, A. Pilotto, A.

Daniele, A. Greco, G. Logroscino.// Biomed Res Int., 2016.

145.Pericak-Vance M. Linkage studies in familial Alzheimer's disease: evidence for chromosome 19 linkage./ M.A. Pericak-Vance, J.L. Bebout, P.C. Gaskell, L.H. Yamaoka, W.-Y. Hung, M.J. Alberts, A.P. Walker, R.J. Bartlett, C.A. Haynes, K.A. Welsh, N.L. Earl, A. Heyman, C.M. Clark, and A.D. Roses.// Am. J. Hum. Genet., 1991. – Vol. 48. – P. 1034–1050.

146.Perry E.K. Neurotransmitter enzyme abnormalities in senile dementia. Choline acetyltransferase and glutamic acid decarboxylase activities in necropsy brain tissue./ E.K. Perry, P.H. Gibson, G. Blessed, R.H. Perry, B.E. Tomlinson.// J Neurol Sci., 1977. – Vol. 34(2). – P. 247–265.

147.Pierrot N. Intraneuronal amyloid–beta1–42 production triggered by sustained increase of cytosolic calcium concentration induces neuronal death./ N. Pierrot, P. Ghisdal, A.S. Caumont, J.N. Octave.// J Neurochem., 2004. – Vol. 88. – P. 1140–

1150.

148. Pike С.J. Sex and the development of Alzheimer’s disease./ С.J. Pike.// Neurosci

Res., 2017. – Vol. 95(1-2). – P. 671–680.

149.Pittel Z. Muscarinic control of amyloid precursor protein secretion in rat cerebral cortex and cerebellum./ Z. Pittel, E. Heldman, J. Barg, R. Haring, A. Fisher.// Brain Res., 1996. – Vol. 742(1-2). – P. 299–304.

150.Price D.L. Alzheimer’s disease: genetic studies and transgenic models./ D.L. Price, R.E.Tanzi, D.R. Borchelt, S.S Sisodia.// Annu. Rev. Genet, 1998. – Vol. 32. – P. 461–493.

151.Price J.L. Neuron number in the entorhinal cortex and CA1 in preclinical Alzheimer Disease./ J.L. Price, A.I. Ko, M.J. Wade, S.K. Tsou, D.W. McKeel, J.C. Morris.// Arch Neurol., 2001. – Vol. 58. – P. 1395–1402.

152.Prut L. The open field as a paradigm to measure the effects of drugs on anxietylike behaviors: a review./ L. Prut, C. Belzung.// Eur. J., 2003. – Vol. 463. – P. 3–33.

153.Qiu W.Q. Insulin–degrading enzyme regulates extracellular levels of amyloid beta–protein by degradation./ W.Q. Qiu, D.M. Walsh, Z. Ye, K. Vekrellis, J. Zhang,

t.me/medicina_free

109

M.B. Podlisny, M.R. Rosner, A. Safavi, L.B. Hersh, D.J. Selkoe.// J Biol Chem., 1998. – Vol. 273. – P. 32730–32738.

154. Querfurth H.W. Alzheimer’s disease./ H.W. Querfurth, F.M. LaFerla.// N Engl J

Med., 2010. – Vol. 362(4). – P. 329–344.

155.R. Recent advances in the multitarget-directed ligands approach for the treatment of Alzheimer's disease./ R. Leon, A.G. Garcia, J. Marco-Contelles.// Med Res Rev., 2013. – Vol. 33. – P. 139–189.

156.Rapoport M. Tau is essential to beta–amyloid–induced neurotoxicity./ M. Rapoport, H.N. Dawson, L.I. Binder, M.P. Vitek, A. Ferreira.// Proc Natl Acad Sci USA, 2002. – Vol. 99. – P. 6364–6369.

157.Rees T. Acetylcholinesterase promotes beta-amyloid plaques in cerebral cortex./ T. Rees.// Neurobiology of Aging, 2003. – Vol. 24. – P. 777–787.

158.Rees T. Memory deficits correlating with acetylcholinesterase splice shift and amyloid burden in doubly transgenic mice./ T. Rees, A. Berson, E. Sklan, L. Younkin, S. Younkin, S. Brimijoin, H. Soreq.// Current Alzheimer Research, 2005. –

Vol. 2. – P. 291–300.

159.Reiman E.M. Correlations between apolipoprotein E epsilon4 gene dose and brain–imaging measurements of regional hypometabolism./ E.M. Reiman, K. Chen, G.E. Alexander, R.J. Caselli, D. Bandy, D. Osborne, A.M. Saunders, J. Hardy.// Proc Natl Acad Sci USA, 2005. – Vol. 102(23). – P. 8299–8302.

160.Reitz C. Epidemiology of Alzheimer disease./ C. Reitz, C. Brayne, R. Mayeux.// Nat Rev Neurol., 2011. – Vol. 7. – P. 137–152.

161.Roher A.E. Amyloid beta peptides in human plasma and tissues and their significance for Alzheimer's disease./ A.E. Roher, C.L. Esh, T.A. Kokjohn, E.M.

Castaño, G.D. Van Vickle, W.M. Kalback, R.L. Patton, D.C. Luehrs, I.D. Daugs, Y.M. Kuo, M.R. Emmerling, H. Soares, J.F. Quinn, J. Kaye, D.J. Connor, N.B. Silverberg, C.H. Adler, J.D. Seward, T.G. Beach, M.N. Sabbagh.// Alzheimers Dement., 2009. – Vol. 5(1). – P. 18–29.

162. Roses A.D. Apolipoprotein E, a gene with complex biological interaction in aging brain./ A.D Roses.// Neurobiol. Disease, 1997. – Vol. 4. – P. 170–186.

t.me/medicina_free

110

163. Rushworth J.V. Lipid rafts: linking Alzheimer's amyloid-β production, aggregation, and toxicity at neuronal membranes./ J.V. Rushworth, N.M. Hooper.// Int J Alzheimers Dis., 2011. – P. 1-14.

164. Rylett R.J. Evidence for high aYnity choline transport in synaptosomes prepared from hippocampus and neocortex of patients with Alzheimer’s disease./ R.J. Rylett, M.J. Ball, E.H. Colhuon.// Brain Res., 1983. – Vol. 289. – P. 169–175.

165.Sampson E.L. Young onset dementia./ E.L. Sampson, J.D. Warren, M.N. Rossor.// Postgrad. Med. J., 2004. – Vol. 80. – P. 125–139.

166.Scheff S.W. Hippocampal synaptic loss in early Alzheimer’s disease and mild

cognitive impairment./ S. W Scheff,., D. A., Price, F. A., Schmitt, E.J. Mufson.//

Neurobiology of Aging, 2006. – Vol. 27(10). – P. 1372–1384.

167.Scheff S.W. Synaptic alterations in CA1 in mild Alzheimer disease and mild cognitive impairment./ S.W. Scheff, D.A. Price, F.A. Schmitt, S.T. DeKosky, E.J. Mufson.// Neurology, 2007. – Vol. 68. – P. 1501–1508.

168.Schenk D. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse./ D. Schenk, R. Barbour, W. Dunn, G. Gordon, H. Grajeda, T. Guido, K. Hu, J. Huang, K. Johnson–Wood, K. Khan, D. Kholodenko, M. Lee, Z. Liao, I. Lieberburg, R. Motter, L. Mutter, F. Soriano, G. Shopp, N. Vasquez, C. Vandevert, S. Walker, M. Wogulis, T. Yednock, D. Games, P. Seubert.// Nature, 1999. – Vol. 400. – P. 173–177.

169.Schneider L.S. Clinical trials and late–stage drug development for Alzheimer’s

disease: an appraisal from 1984 to 2014./ L.S. Schneider, F. Mangialasche, N. Andreasen, H. Feldman, E. Giacobini, R. Jones, V. Mantua, P. Mecocci, L. Pani, B. Winblad, M. Kivipelto.// J Intern Med., 2014. – Vol. 275. – P. 251–283.

170.Segal M. Dendritic spines and long–term plasticity./ M. Segal.// Nat Rev Neurosci., 2005. – Vol. 6. – P. 277–284.

171.Selkoe D.J. Alzheimer's disease is a synaptic failure./ D.J. Selkoe.// Science, 2002. – Vol. 298. – P. 789–791.

172.Selkoe D.J. Alzheimer's disease: genes, proteins, and therapy./ D.J. Selkoe.// Physiol Rev., 2001. – Vol. 81. – P. 741–766.

t.me/medicina_free